本文選題：糖尿病 + 型��； 參考：《重慶醫(yī)學》2017年02期

【摘要】：目的評價Dulaglutide治療2型糖尿病的有效性和安全性。方法計算機檢索Cochrane圖書館、PubMed、OVID、Medline、Embase、知網(wǎng)、萬方、維普等數(shù)據(jù)庫,按Cochrane系統(tǒng)評價的方法評價納入研究的質(zhì)量,并使用RevMan 5.2軟件進行Meta分析。結(jié)果共納入10項研究,6 699例患者。Meta分析結(jié)果顯示,Dulaglutide在降低糖化血紅蛋白(HbA1c)[陽性對照組:均數(shù)差(MD)=-0.32,95%CI(-0.42,-0.22),P0.01;安慰劑:MD=-1.07,95%CI(-1.16,-0.99),P0.01]、空腹血糖(FPG)[陽性對照組:MD=-0.60,95%CI(-0.84,-0.36),P0.01;安慰劑:MD=-1.86,95%CI(-1.88,-1.84),P0.01]、體質(zhì)量方面[陽性對照組:MD=-0.95,95%CI(-1.69,-0.21),P=0.010;安慰劑:MD=-1.31,95%CI(-2.13,-0.49),P=0.002]優(yōu)于陽性對照組或安慰劑。安全性方面,Dulaglutide與陽性對照組及安慰劑相比,低血糖發(fā)生風險和總不良反應發(fā)生率差異無統(tǒng)計學意義(P0.05)。結(jié)論 Dulaglutide治療2型糖尿病安全有效。
[Abstract]:Objective to evaluate the efficacy and safety of Dulaglutide in the treatment of type 2 diabetes. Methods the Cochrane library was searched by computer for the database of Cochrane Medline. The quality of the study was evaluated according to the method of Cochrane system evaluation, and the Meta analysis was carried out with RevMan 5.2 software. 緇撴灉鍏辯撼鍏，

本文編號：1910799